In working-age women with incident invasive breast cancer, treated with lumpectomy plus either whole-breast irradiation or brachytherapy, subsequent mastectomy risk was similar for patients treated with endocrine therapy and either radiation strategy. In contrast, for patients treated without endocrine therapy, the risk was notably higher in those receiving brachytherapy. Endocrine therapy status, and by extrapolation, hormone receptor status, may be a helpful discriminatory factor when contemplating brachytherapy in such patients.
Introduction
Breast brachytherapy is a popular adjuvant radiation therapy modality, intended to decrease local tumor recurrence risks after lumpectomy (1) . In recent years breast brachytherapy has gradually replaced traditional whole-breast irradiation (WBI) in a subset of older breast cancer patients, used in lieu of WBI in approximately 16% of eligible patients aged 65 years and older. Breast brachytherapy is generally accepted as a standard treatment option in such older patients, especially in those with a low predicted risk of recurrence (2, 3) .
In younger patients, however, the suitability of breast brachytherapy remains controversial, with conflicting statements from current treatment guidelines. American Society for Radiation Oncology (ASTRO) guidelines identify either age <60 years or estrogen receptor (ER)-negative status alone as sufficient to categorize a patient as "cautionary" or "unsuitable" for breast brachytherapy (4) . In contrast, American Brachytherapy Society (ABS), Groupe Européen de CuriethérapieeEuropean Society for Therapeutic Radiology and Oncology (GEC-ESTRO), and American Society of Breast Surgeons (ASBS) guidelines classify patients as young as 45 to 50 years as "acceptable" for brachytherapy. Furthermore, none of these guidelines deems ER-negative status alone sufficient to disqualify patients from brachytherapy (5) (6) (7) .
Existing data are insufficient for reconciling these divergent recommendations. Although it is clear that younger age and negative ER status are risk factors for inbreast tumor recurrence (8) (9) (10) (11) (12) , it remains unclear whether, in patients with these risk factors, recurrences after brachytherapy occur more frequently than after WBI (5). Thus, not surprisingly, there is considerable heterogeneity in breast brachytherapy utilization patterns associated with the conflicting and insufficient data (3) . Approximately 60% to70% of current patients in the United States treated with breast brachytherapy are classified as ASTRO "cautionary" or "unsuitable," suggesting that these guidelines may be viewed as overly restrictive (1, 13) .
Heterogeneous practice patterns, discrepancies in expert opinions, and high prevalence of care discordant with current guidelines all point to the pressing need to compare utilization and efficacy outcomes in younger, higher-risk patients treated with brachytherapy versus WBI. Such a comparison could inform evolving selection criteria for breast brachytherapy. Accordingly, in a national, contemporary cohort of women with incident breast cancer aged 64 years and younger, we directly compared (1) radiation treatment utilization patterns; (2) risks of subsequent mastectomy; and (3) costs of radiation treatment in patients treated with brachytherapy versus WBI.
Methods and Materials Dataset
The MarketScan Commercial Claims and Encounters database (Truven Health Analytics, Ann Arbor, MI) is an employment-based, health care claims database including employees and beneficiaries. The data include claims from approximately 45 large, self-insured employers who contract with Truven Health Analytics to manage the cost and design of their health care plans, and also include employees and dependents who receive their health care coverage from small-and medium-sized firms (14, 15) .
Cohort selection
On the basis of an algorithmic claims approach similarly utilized in prior studies (15, 16) , we searched diagnosis and procedure claims to initially identify 59,956 women aged 18 to 64 years with breast cancer, treated between 2003 and 2010 using lumpectomy followed by radiation. To ensure a homogeneous population treated with definitive intent, we excluded patients with metastatic cancer, as well as patients who underwent mastectomy before radiation treatment, those who failed to receive an entire radiation course (as indicated by no simulation or delivery codes), and those receiving a combination of WBI plus brachytherapy; our final sample yielded 45,884 patients (Table E1 ; available online at www.redjournal.org).
Radiation treatment
Radiation treatment delivered within 12 months of lumpectomy was determined using Common Procedural Terminology and International Classification of Diseases (version 9) procedure codes, and classified as follows: WBI (including external beam radiation treatment with or without intensity modulated radiation therapy [IMRT]); or brachytherapy, including specific indicators of singleversus multi-channel applicator (Table E2 ; available online at www.redjournal.org).
Subsequent mastectomy and other covariates
In accordance with published methods, subsequent mastectomy was defined as a procedure code for mastectomy occurring at any time between 1 year after lumpectomy and date of last follow-up (17) . Locoregional tumor recurrences are not available in this data set. The MarketScan (administrative) enrollment file provided covariate data including age (which was available as a continuous variable, but also classified dichotomously a priori into Age<50 (years) or Age!50, according to brachytherapy treatment guidelines) (4, 5) , as well as Census Bureau geographic region (18) . Inpatient and outpatient claims files were used to define axillary lymph node surgery, axillary lymph node involvement, and use of systemic chemotherapy (including a specific indicator for trastuzumab treatment). The variable "systemic chemotherapy (yes/no)" does not include endocrine therapy. Separately, the National Drug Code pharmacy file was used to determine endocrine therapy use and to supplement definitions of chemotherapy and trastuzumab (Table E3 ; available online at www.redjournal.org). Patients were considered "Endocrineþ" if they filled a prescription for tamoxifen, anastrozole, letrozole, or exemestane within À3 to þ12 months of surgery. Of note, pathologic hormone receptor status and long-term endocrine therapy compliance were not available in this dataset. Modified Charlson comorbidity score was derived from claims during the 3 months preceding lumpectomy, and specific claims for diagnoses of cardiovascular disease and diabetes were also identified (19) . Area-level socioeconomic variables were derived using linkage with the Area Health Resource File, according to patients' county and health service area (HSA) of residence in the year of their treatment. The HSA-level surgeon and radiation oncologist density was calculated using HSA population density.
Risk subgroups by age and endocrine therapy status
We prospectively stratified patients into risk groups according to age (Age<50 vs Age!50) and endocrine therapy status (EndocrineÀ vs Endocrineþ), including the following combinations defined a priori: EndocrineÀ/ Age<50; EndocrineÀ/Age!50; Endocrineþ/Age<50; and Endocrineþ/Age!50.
Costs of care
Radiation treatment-related costs were calculated according to the total amount reimbursed by the insurer to providers for radiation-related claims occurring within 1 year of lumpectomy, including claims related to radiation treatment planning and delivery and placement of a brachytherapy catheter. Costs were adjusted for inflation and normalized to the year 2013 using the Medicare Economic Index (20) .
Statistical analysis
To address our first objective, we calculated percent use of brachytherapy by year, standardized by geographic region to account for fluctuations in the geographic composition of the MarketScan cohort over time (21) . Brachytherapy use rates by state were calculated to demonstrate variations in local practice patterns.
Temporal trends in radiation treatment utilization were tested using the Cochran-Armitage trend test. Univariate predictors of radiation treatment selection were evaluated using the Pearson c 2 test. Multivariate logistic models identified independent predictors of selection for brachytherapy versus WBI. Goodness of fit was assessed using the method of Hosmer and Lemeshow.
To address our second objective, we calculated cumulative incidence of subsequent mastectomy using the Kaplan-Meier method, with patients censored at date of last follow-up. Unadjusted risk of subsequent mastectomy for patients treated with brachytherapy versus WBI was compared using the log-rank test. Adjusted subsequent mastectomy risks were determined using multivariate Cox proportional hazards models. Covariates for multivariate models were selected a priori according to clinical relevance and/or univariate significance (P<.25). Proportionality assumption was verified using visual inspection of the log(-log) plot and proportionality test. Models tested for prespecified interactions between radiation treatment type and age, endocrine therapy status, and combined age/ endocrine therapy risk group. Stratum-specific hazard ratios (HRs) were generated using interaction terms. A subgroup analysis further divided brachytherapy treatment to specifically compare outcomes in patients treated with singleversus multi-channel applicators.
To address our third objective, we compared differences in radiation-related costs for patients treated with WBI with or without IMRT versus brachytherapy with single-versus multi-catheters using the Wilcoxon 2-sample test. All analyses assumed 2-tailed a Z 0.05 and were conducted using SAS version 9.3 (SAS Institute, Cary, NC). Our study was approved by the University of Texas MD Anderson Cancer Center institutional review board.
Results

Patient sample
Of 45,884 women, median follow-up was 2.4 years (interquartile range 1.6-3.8 years), and median age was 54 years (interquartile range 48-59 years). Overall frequency of brachytherapy use was 6.8% (nZ3134 of 45,884) but significantly increased over the study period, from 1.7% in 2003 to 9.5% in 2010 (P trend <.001) (Fig. 1A) . State-level practice patterns varied widely (P<.001), with the frequency of brachytherapy ranging from a low of 0 in Alaska (0 of 57), Hawaii (0 of 9), and Vermont (0 of 51) to a high of 23.3% in Arizona (105 of 451). State-level variation persisted even in patients who were in the groups Age<50 (P<.001) or EndocrineÀ (P<.001) ( Fig. 2A, B) .
Brachytherapy utilization
Frequency of brachytherapy utilization by year increased within each age and endocrine therapy risk subgroup: in Age<50 patients (nZ14,087), from 0.6% to 4.9% (P<.001); in Age!50 patients (nZ31,797), from 2.2% to 11.3% (P<.001); in EndocrineÀ patients (nZ20,092), 1.3% to 9.4% (P<.001); in Endocrineþ patients (nZ25,792), 1.9% to 9.7% (P<.001) (Fig. 1B, C) . However, age influenced treatment selection more than endocrine therapy status, as demonstrated by absolute differences in the frequency of selection for brachytherapy versus WBI. Specifically, 17% of brachytherapy patients versus 32% of WBI patients were Age<50 (P<.001); whereas 41% of brachytherapy patients versus 44% of WBI patients were EndocrineÀ (PZ.003) ( Table 1) .
On multivariate analysis, younger patients were less likely than older patients to be selected for brachytherapy ( (Table E4 ; available online at www.redjournal.org). Other factors associated with brachytherapy use included no chemotherapy, no axillary lymph node involvement, history of diabetes, and higher area-level median household income. Geographic and local practice patterns suggested higher brachytherapy use in the South and in areas with lower density of radiation oncologists (Table 1; Table E4 ; available online at www.redjournal.org).
Subsequent mastectomy risk
Five-year subsequent mastectomy risk was 6.6% in patients treated with brachytherapy versus 4.4% in patients treated with WBI (P<.001) (Fig. 3) (Fig. 3) . We observed no significant differences in subsequent mastectomy outcomes by type of brachytherapy applicator (HR 0.77, 95% CI 0.49-1.20; PZ.25 for multi-channel brachytherapy, with single-channel brachytherapy as referent). These utilization patterns reflect the prevailing guidelines available during our study period (specifically ABS and ASBS guidelines), which recommended consideration of age but not ER status in selecting patients for brachytherapy.
Treatment costs
We were surprised to find that though endocrine therapy status was less important for treatment selection, endocrine therapy status was the most important, among all the measured variables, predictor of differences in early subsequent mastectomy outcomes for brachytherapy versus WBI. Among EndocrineÀ patients, the absolute 5-year risk of subsequent mastectomy was 15.4% higher with brachytherapy compared with WBI for those Age<50 and 3.7% higher for those Age!50. Among Endocrineþ patients, however, the absolute 5-year risk of subsequent mastectomy was only 1.0% higher with brachytherapy compared with WBI for those Age<50 and 1.7% higher for those Age!50. These findings suggest that contemporary trends in patient selection for brachytherapy may not be appropriately riskbased, influenced strongly by age but only minimally by endocrine therapy status.
In light of consensus statements and guidelines written by professional societies that currently guide use of breast brachytherapy, our results are hypothesis-generating, particularly as mature data from phase 3 trials are awaited. In particular, Endocrinee status in our study is a surrogate variable for pathologic hormone receptor status. Additional validating studies with detailed biological marker information, including actual receptor status as well as the influence of other clinico-pathologic variables such as Her2/neu status, triple-negative status, margins, and grade, along with studies with detailed information on hormone therapy use and compliance, may further influence future consensus recommendations based on hormone receptor status. With this caution in mind, regarding the ASTRO consensus statement, our findings may suggest brachytherapy as a suitable treatment for certain patients with ERþ disease, aged 50 to 60 years, particularly if treated with endocrine therapy. For patients aged <50 years, brachytherapy may also be an acceptable option, with only small absolute differences in early subsequent mastectomy risks for this group, for example 3.7% found in our study. However, careful long-term follow-up in such patients remains warranted. In particular, given that the median follow-up in our study was 2.4 years, our results reflect early subsequent mastectomy event rates, which could change over time, especially in patients taking endocrine therapy who may experience later failures (4) . With regard to the ABS and GEC-ESTRO recommendations, our findings commend a more cautious stance on use of brachytherapy in patients aged <50 years not treated with endocrine therapy. It should be noted that both groups do not recommend brachytherapy for women aged <50 years, but our data suggest that this Abbreviations: E Z endocrine; HSA Z health services area; IMRT Z intensity modulated radiation therapy; WBI Z whole-breast irradiation. * Thirty-five patients treated with brachytherapy could not be classified as single-or multi-channel.
recommendation may need to be restricted to those younger patients who do not receive endocrine therapy, or by extrapolation, ERÀ patients, who had the highest risk differential between brachytherapy and WBI in our study (5, 6) . The ASBS considers brachytherapy acceptable in women aged 45 years and older regardless of ER status; our findings would suggest inclusion of ER status may be additive to the current criteria (7). Although randomized trials are the gold standard to inform clinical decision making, the recently completed Log-rank P <.001 P value for interaction terms: *0.96 **0.34 ***0.53 A B Fig. 3 . Risk of subsequent mastectomy. (A) Overall cumulative incidence of subsequent mastectomy for brachytherapy versus whole-breast irradiation (WBI). Survival curves depict cumulative incidence of subsequent mastectomy by type of radiation therapy. Shaded areas indicate 95% confidence bands. (B) Unadjusted and adjusted subsequent mastectomy risks stratified by age and endocrine (E) status. Adjusted hazard ratios are derived from the multivariate model in Table 2 but are calculated using the appropriate interaction term to measure effect sizes of type of radiation therapy in specific subgroups, such as Age<50 and Age!50. EBRT Z external beam radiation therapy.
trials evaluating brachytherapy may be insufficient to clarify indications in younger patients with high-risk features. Specifically, the Radiation Therapy and Oncology
Group protocol 0413 likely enrolled fewer than 600 patients treated with brachytherapy, of whom only a fraction would have had ERe tumors or age <50 years (22) . In contrast, 1606 similar patients are included in the present analysis, patients who did not receive endocrine therapy (and who were presumably more likely ERÀ), allowing the present study substantial power to measure effect sizes relative to endocrine therapy. Similarly, the GEC-ESTRO randomized trial has limited ability to inform US brachytherapy practice patterns, because this study used interstitial brachytherapy, which treats 2 cm of tissue beyond the tumor bed, considerably greater than the 1 cm of tissue beyond the tumor bed treated with single-entry catheters commonly used in the United States (23).
Our findings regarding the relative cost of single and multi-channel brachytherapy in comparison with WBI with or without IMRT are uniquely suited to facilitate assessment of the value of radiation modalities in younger women with private insurance. Brachytherapy confers value to patients as total treatment time is decreased and radiationrelated fatigue may be lessened (24) , yet such gains could be offset by higher recurrence risks or much higher costs, either from brachytherapy itself or salvage treatment (such as for recurrent disease, though this outcome was not directly measured in the present study) (25) . Prior literature has sought to estimate value using costs derived from Medicare reimbursement (25, 26) , but such approaches are dated given changes to brachytherapy reimbursement that occurred in 2009 (27) and further do not extend to younger patients with private insurance.
Several limitations of this work are worthy of consideration. First, results only apply to younger patients with private insurance. Second, patients with ductal carcinoma in situ were excluded; findings should not be extended to this population. Third, follow-up is inherently limited in studies of patients with private insurance, for whom insurance changes are not uncommon. Fourth, although subsequent mastectomy is a clinically relevant endpoint, it is not necessarily equivalent to local failure, because mastectomy may be performed for other reasons such as treatment of severe complications, contralateral breast cancer, risk-reduction against future breast cancers, or even as a component of surgery for a regional recurrence. Nevertheless, the literature indirectly validates subsequent mastectomy as an outcome whose risk is reduced by standard WBI (28) (29) (30) (31) . Additionally, endocrine therapy status was defined by filling a prescription for endocrine therapy, not by actual testing for ER expression. Thus, the Endocrinee group includes both ERþ patients who did take endocrine therapy in addition to ERÀ patients for whom endocrine therapy is not beneficial. Nevertheless, our finding of a 2-fold reduction in subsequent mastectomy risk attributed to Endocrineþ status underscores the clinical relevance of this definition (32) . Future studies with detailed pathologic variables, for example tumor size, lymphovascular invasion status, and grade, may also seek to quantify the degree to which each of these clinical features potentially modifies the risk associated with endocrine therapy status. Use of these surrogate variables as well as the possibility of residual confounding remain limitations of a claims-based, retrospective cohort analysis (33) , and thus our results require interpretation also in the context of additional validating cohorts and awaited prospective data. Moreover, the range of absolute differences in subsequent mastectomy outcomes emphasizes the need to consider both the statistical and clinical significance of these results, as well as individual patient preference, when potentially extrapolating these findings to the clinical setting. Finally, the years of this study, from 2003 to 2010, span a time period when the new technology of breast brachytherapy had more recently been approved by the US Food and Drug Administration, so this study tends to reflect the learning curve of early adopters. Future studies may serve to reflect continuing temporal trends in outcomes of experts or experienced practitioners. In summary, although age drives current guidelines and clinical practice patterns for brachytherapy treatment selection, endocrine therapy status seems to be a more valuable discriminatory factor predicting subsequent mastectomy risk after brachytherapy treatment as compared with WBI for younger patients. Clinicians and guidelines should acknowledge endocrine therapy status as a key factor relevant to brachytherapy selection criteria.
